Corcept Therapeutics (CORT) Stock Price, Quote & News

Company Profile

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery....

Industry: Biotechnology

Sector: Healthcare

Phone: 650 327 3270

Website: www.corcept.com

Address:

101 Redwood Shores Parkway, Redwood City, United States

Bubbarayjr62 May. 30 at 1:49 PM

$CORT I don't believe the Market knows or has digested the NEW data below. From the abstract: Moreover, a consistent OS benefit was observed irrespective of whether a taxane was used in the most recent regimen: taxane in the last regimen (n = 73, HR 0.67 [95% CI, 0.38 to 1.19], median difference 3.9 months) and no taxane in the last regimen (n = 308, HR 0.63 [95% CI, 0.48 to 0.82], median difference 4.2 months). It appears that the Overall Survival (OS) benefit is not JUST with Taxane regimens. This is an important factor because the FDA approved indication is for use WITH Taxanes (see below) Package Insert: LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. CORT will file for a label expansion to help more women imo

1 · Reply

Orbit100 May. 29 at 6:07 PM

$CORT REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan. 22, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company's pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival (OS) primary endpoint. It reduced 35% of the death rate for women with the cancer. Invest huge with a big vision of Corcept. It hit $115 more than a year ago. The stock is easy triple for the long term investors.

0 · Reply

Bubbarayjr62 May. 29 at 10:37 AM

$CORT ASCO: Big Splash for CORT Three abstracts listed on ASCO's website: SYNERGY: A phase 1b/2 study of nenocorilant, a selective glucocorticoid receptor antagonist, plus nivolumab in patients with advanced solid malignancies. TRIDENT: A phase 2 study of relacorilant plus nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023). https://www.asco.org/search?userInput=corcept

1 · Reply

gucag006 May. 29 at 9:08 AM

$CORT This is an incredible company to invest and ride to the land of riches: - Korlym (CS) is a $1B blockbuster drug already. - Lifyoli (PROC) is on its way to become the 2nd $1B blockbuster drug. - Relacorilant (CS) will start helping CS patients, who previously couldn't take Korlym, in 2027 such as female CS sufferers. Relacorilant (CS) will replace Korlym to become a multi-$B blockbuster drug in a few years. - Dazucorilant (ALS) will be the 4th $1B blockbuster drug in 2028. - Miricorilant (MASH) will be the 5th. - Nenocorilant will be the 6th. And the story carries on into the 2030s and beyond. GLTA!

1 · Reply

gucag006 May. 29 at 8:49 AM

$CORT In case you wonder how CORT's holding Korlym against generic from Teva, please read on and give some credits and respect to the management team of CORT:

1 · Reply

Night_Owl_Biotech May. 29 at 3:05 AM

The $XBI has traded higher in 4 out of the last 5 trading sessions, surging over 3% during the 5-day period. Common sense might suggest commercial-stage oncology focused bios should, as a peer group, more or less keep up with the XBI but they did not. 13 out of 20 (with MCs over $570MM) have traded lower over this 5-day period. $IBRX URGN ARVN $GERN & ANAB have traded lower most days. $IOVA has clearly been an outlier over the last 5 days, warranted or not, as has $CORT We're unaware of any recent catalysts nor inflection points for either. The UBS upgrade was well 2 weeks ago + Recall IOVA surged to $5.50 in March? As always, this is not investment advice.

0 · Reply

bubbarayjr May. 28 at 9:28 PM

$CORT Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $135 from $110

0 · Reply

Merlintrader May. 27 at 11:28 PM

$CORT

0 · Reply

EingeLTrade May. 27 at 8:13 PM

$CORT did 110% since March. Three huge green monthly candles in a row 😮

0 · Reply

XQuise May. 27 at 7:47 PM

$CORT 🤑😋😋

0 · Reply

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

2026-05-28T12:08:48.000Z - 2 days ago

Corcept Therapeutics price target raised to $135 from $110 at Canaccord

2026-05-28T10:10:27.000Z - 2 days ago

Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright

2026-05-27T14:36:43.000Z - 3 days ago

Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant

May 27, 2026, 8:00 AM EDT - 3 days ago

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome

2026-05-13T13:38:36.000Z - 17 days ago

Corcept Therapeutics upgraded to Buy from Neutral at UBS

2026-05-13T09:35:12.000Z - 17 days ago

Corcept Therapeutics upgraded to Buy from Neutral at UBS

2026-05-04T10:17:31.000Z - 26 days ago

Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright

2026-05-01T11:37:49.000Z - 4 weeks ago

Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler

2026-04-30T21:06:37.000Z - 4 weeks ago

Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study

Apr 30, 2026, 5:00 PM EDT - 4 weeks ago

Corcept Therapeutics Earnings Call Transcript: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 4 weeks ago

Corcept Therapeutics Earnings release: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 4 weeks ago

Corcept Therapeutics Quarterly report: Q1 2026

2026-04-30T20:28:44.000Z - 4 weeks ago

Corcept Therapeutics reports Q1 EPS (30c), consensus (14c)

2026-04-30T20:28:17.000Z - 4 weeks ago

Corcept Therapeutics raises FY26 revenue view to $950M-$1.05B, consensus $933.2M

Apr 30, 2026, 4:05 PM EDT - 4 weeks ago

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

Apr 30, 2026, 4:05 PM EDT - 4 weeks ago

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Apr 23, 2026, 4:05 PM EDT - 5 weeks ago

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Apr 21, 2026, 1:09 PM EDT - 5 weeks ago

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

Apr 17, 2026, 8:00 AM EDT - 6 weeks ago

Corcept Therapeutics Proxy statement: Proxy filing

2026-04-10T20:56:08.000Z - 7 weeks ago

Corcept Therapeutics presents final overall survival data from ROSELLA trial

Apr 10, 2026, 4:45 PM EDT - 7 weeks ago

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

2026-04-02T09:40:29.000Z - 2 months ago

Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims

2026-03-29T14:55:40.000Z - 2 months ago

Corcept Therapeutics presents data from Momentum trial at ACC 2026

Mar 28, 2026, 2:45 PM EDT - 2 months ago

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

2026-03-26T12:50:58.000Z - 2 months ago

Corcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe Research

2026-03-26T11:17:59.000Z - 2 months ago

Corcept Therapeutics price target raised to $110 from $100 at Canaccord

2026-03-25T18:25:15.000Z - 2 months ago

Corcept Therapeutics price target raised to $110 from $100 at Canaccord

Mar 25, 2026, 1:18 PM EDT - 2 months ago

Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer

2026-03-25T16:50:44.000Z - 2 months ago

Corcept confirms FDA approves Lifyorli for platinum-resistant ovarian cancer

Mar 25, 2026, 12:43 PM EDT - 2 months ago

FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

2026-03-25T16:39:23.000Z - 2 months ago

Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?

TEVA

2026-03-25T16:10:43.000Z - 2 months ago

Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright

2026-03-25T16:06:09.000Z - 2 months ago

Corcept Therapeutics rises 28.6%

Mar 18, 2026, 5:35 PM EDT - 2 months ago

Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated

Mar 11, 2026, 4:48 PM EDT - 2 months ago

Corcept Therapeutics Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 6:00 PM EDT - 2 months ago

REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026

Feb 24, 2026, 5:00 PM EST - 3 months ago

Corcept Therapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

Corcept Therapeutics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

Corcept Therapeutics Earnings release: Q4 2025

Feb 24, 2026, 4:05 PM EST - 3 months ago

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

Feb 19, 2026, 4:00 PM EST - 3 months ago

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

Feb 17, 2026, 4:05 PM EST - 3 months ago

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call

Feb 9, 2026, 4:54 AM EST - 3 months ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

Jan 30, 2026, 2:20 PM EST - 4 months ago

Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application

Jan 30, 2026, 10:36 AM EST - 4 months ago

Corcept shares tumble after FDA letter reveals warnings before drug rejection

Jan 22, 2026, 8:13 AM EST - 4 months ago

Corcept's cancer drug meets main goal in late-stage trial

Jan 22, 2026, 8:00 AM EST - 4 months ago

Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Jan 15, 2026, 10:31 AM EST - 4 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CTRE DCOM DOCN ENVA

Jan 14, 2026, 9:52 PM EST - 4 months ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT

Bubbarayjr62 May. 30 at 1:49 PM

1 · Reply

Orbit100 May. 29 at 6:07 PM

0 · Reply

Bubbarayjr62 May. 29 at 10:37 AM

1 · Reply

gucag006 May. 29 at 9:08 AM

1 · Reply

gucag006 May. 29 at 8:49 AM

$CORT In case you wonder how CORT's holding Korlym against generic from Teva, please read on and give some credits and respect to the management team of CORT:

1 · Reply

Night_Owl_Biotech May. 29 at 3:05 AM

0 · Reply

bubbarayjr May. 28 at 9:28 PM

$CORT Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $135 from $110

0 · Reply

Merlintrader May. 27 at 11:28 PM

$CORT

0 · Reply

EingeLTrade May. 27 at 8:13 PM

$CORT did 110% since March. Three huge green monthly candles in a row 😮

0 · Reply

XQuise May. 27 at 7:47 PM

$CORT 🤑😋😋

0 · Reply

Orbit100 May. 27 at 5:00 PM

$CORT More than a week ago Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%. Frankly speaking, it is too conservative prediction for $105 when 52 weeks high last year was $115. Corcept has many drugs that are going through FDA approval including the overian cancer drug. This stock is a great keep for the long term and could be your big ticket for great retirement. Keep away from the keyboard, This stock is still quite cheap and great to add or to get in.

0 · Reply

Merlintrader May. 27 at 4:13 PM

$CORT CORT Update: Relacorilant Cushing’s NDA Moves Back Toward FDA Review https://www.merlintrader.com/corcept-therapeutics-cort-stock-hub-2026/

0 · Reply

gucag006 May. 27 at 2:38 PM

$CORT @jvoms Indeed, - Korlym is still selling well with AG in place; - Relacorilant/chemo for PROC on its way to blockbuster; - Relacorilant for CS with PDUFA by EOY; - Dazucorilant for ALS in preparation for P3 trial; - Miricorilant for NASH/MASH in early stage clinical trials; - Nenocorilant for solid tumors on the horizon. Totally agree on the comments about the management. I took advantage of the last dip and added 3k shares @$40. We're on our way back to $80 now, and soon to $120, $200, $250 .....

0 · Reply

notreload_ai May. 27 at 2:04 PM

$CORT will resubmit its NDA for relacorilant to treat Cushing’s syndrome after positive FDA feedback. https://notreload.xyz/xy/corcept-resubmits-relacorilant-nda-for-cushings-syndrome/

0 · Reply

StocktwitsNews May. 27 at 1:57 PM

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally $CORT https://stocktwits.com/news/equity/markets/cort-stock-rally-highest-2026-levels-nda-resubmission/cZggOaPRer7

0 · Reply

gucag006 May. 27 at 1:44 PM

$CORT Quote from the press release of the NDA resubmission: "Following issuance of its complete response letter, the FDA asked us to conduct additional analyses of our NDA data," said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. "Based on the positive outcome of those analyses and the productive tenor of our discussions, we plan to resubmit our NDA in the coming weeks. The agency has told us to expect a Prescription Drug User Fee Act (PDUFA) date six months after the date of our submission. We appreciate the FDA’s continued engagement with our efforts to bring relacorilant’s benefits to patients with hypercortisolism." After CRL, the following must have happened: - conducted additional analyses; - reviewed with FDA; - FDA deemed the new analyses acceptable to support a class 2 resubmission (6 months review); - In the final stage of the resubmission preparation (within weeks); Without FDA's positive feedbacks these would not be possible. also, no mention of new trial!

1 · Reply

Bubbarayjr62 May. 27 at 1:26 PM

$CORT Nope, it will go even higher but not in a single day. It will reach another all time high ($117++) after approval (very early 2027) imo

0 · Reply

moorenard1 May. 27 at 1:23 PM

$CORT When CRL hit stock dropped from 90s to $35. Will stock increase $60 on this news? Probably not. Should it go up $20? Absolutely.

0 · Reply

Bubbarayjr62 May. 27 at 1:10 PM

$CORT WOW! GREAT NEWS!!! REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it will resubmit its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome. “Following issuance of its complete response letter, the FDA asked us to conduct additional analyses of our NDA data,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “Based on the positive outcome of those analyses and the productive tenor of our discussions, we plan to resubmit our NDA in the coming **WEEKS**. The agency has told us to expect a Prescription Drug User Fee Act (PDUFA) date SIX MONTHS after the date of our submission". VERY POSITIVE FDA VIBES IMO

0 · Reply

Daniech0514 May. 27 at 1:09 PM

$CORT I like the words in the press release from our CEO "Based on the positive outcome of those analyses and the productive tenor of our discussions, we plan to resubmit our NDA" I just hope the are right about the tenor this time!

0 · Reply

TwongStocks May. 27 at 12:02 PM

$CORT Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome https://www.businesswire.com/news/home/20260527119062/en/Corcept-to-Resubmit-its-New-Drug-Application-for-Relacorilant-as-a-Treatment-for-Patients-with-Cushings-Syndrome "The agency has told us to expect a Prescription Drug User Fee Act (PDUFA) date six months after the date of our submission." ^ Suggests they anticipate a Class 2 review. 6 month review period will put the new PDUFA date around end of November. CORT should receive confirmation of the classification and new PDUFA date within 30 days.

0 · Reply

EingeLTrade May. 26 at 7:26 PM

$CORT slow & steady bearish gap closing

0 · Reply

Market Cap	7.46B
Revenue (ttm)	761.41M
Net Income (ttm)	99.65M
EPS (ttm)	N/A
PE Ratio	195.37
Forward PE	128.41
Profit Margin	13.09%
Debt to Equity Ratio	0.00

Volume	775,000
Avg Vol	1,504,402
Day's Range	N/A - N/A
Shares Out	107.35M
Stochastic %K	97%
Beta	0.36
Analysts	Strong Sell
Price Target	$88.00